Safety, pharmacokinetics, and efficacy of abexinostat, an novel histone deacetylase inhibitor, in Chinese patients with relapsed/refractory B cell non-Hodgkin lymphoma: a Phase 1 study

Authors

Zucheng Xie (ORCID: https://orcid.org/0000-0002-7910-9660)
Lin Gui (ORCID: https://orcid.org/0000-0002-8054-9524)
Yan Qin (ORCID: https://orcid.org/0000-0002-2958-8122)
Yuankai Shi (ORCID: https://orcid.org/0000-0002-8685-6744)
Zhenyu Li (ORCID: https://orcid.org/0000-0002-3850-7451)
Peng Liu (ORCID: https://orcid.org/0000-0002-2653-0718)
Ran Tao (ORCID: https://orcid.org/0000-0002-6206-1744)
Xinrui Chen (ORCID: https://orcid.org/0000-0001-8780-4076)
Jianliang Yang

Institutions

Xuzhou Medical College (CN)
Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
National Cancer Center (US)
NARI Group (China) (CN)

Publication Details

Journal: BMC Cancer
Published: 2025-05-30
DOI: https://doi.org/10.1186/s12885-025-14370-y
Citations: 3
Primary Topic: Histone Deacetylase Inhibitors Research
Type: article
Field-Weighted Citation Impact: 2.42

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Safety, pharmacokinetics, and efficacy of abexinostat, an novel histone deacetylase inhibitor, in Chinese patients with relapsed/refractory B cell non-Hodgkin lymphoma: a Phase 1 study

Zucheng Xie, Lin Gui, Yan Qin, Yuankai Shi et al.

May 30, 2025

3 citations

BMC Cancer

Histone Deacetylase Inhibitors Research

2.42

article

Safety, pharmacokinetics, and efficacy of abexinostat, an novel histone deacetylase inhibitor, in Chinese patients with relapsed/refractory B cell non-Hodgkin lymphoma: a Phase 1 study

Zucheng Xie, Lin Gui, Yan Qin, Yuankai Shi, Zhenyu Li, Peng Liu, Ran Tao, Xinrui Chen, Jianliang Yang

May 30, 2025article en

3 citations

Abstract

No abstract available for this paper.

BMC CancerVol. 25(1)

Xuzhou Medical College (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), National Cancer Center (US), NARI Group (China) (CN)

Good health and well-being

Openalex Percentile: Top 11%

Histone Deacetylase Inhibitors Research

2.42

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.